We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
CVS Group Plc | AQSE:CVSG.GB | Aquis Stock Exchange | Ordinary Share | GB00B2863827 | Ordinary Shares 20p |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 955.00 | 740.00 | 1,170.00 | 952.40 | 925.00 | 925.00 | 193 | 16:29:38 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCVSG
RNS Number : 5979S
CVS Group plc
10 March 2023
10 March 2023
CVS Group Plc
("CVS" or the "Company")
Exercise of SAYE Options, PDMR Dealing
and Total Voting Rights
CVS, one of the UK's leading providers of integrated veterinary services, announces that on 10 March 2023, options over a total of 1,667 ordinary shares of 0.2 pence each (the "Ordinary Shares") were exercised under the CVS Group 2019 SAYE Plan (2019/2023), at an exercise price of GBP8.63 (the "SAYE Exercise").
The sum of 1,667 Ordinary shares were satisfied from the shares held in the Employee Benefit Trust managed by JTC Group. As a result, no new Ordinary Shares were issued to satisfy the SAYE Exercise.
Ben Jacklin, Chief Operating Officer exercised options over 709 Ordinary Shares in the Company. The balance of the options were exercised by certain other employees and former employees of the Company.
Following his option exercise, Ben Jacklin holds a beneficial interest in 23,093 Ordinary Shares in the Company, representing approximately 0.032 per cent of the total voting rights of the Company, calculated on the same basis.
Following the SAYE Exercise, the Company has a total issued share capital of 71,385,048 Ordinary Shares each carrying one voting right. The Company holds no Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company will be 71,385,048. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.
Contacts:
CVS Group plc via Camarco
Richard Fairman, CEO
Jenny Farrer, Company Secretary
Peel Hunt LLP (Nominated Adviser & Broker) +44 (0)20 7418 8900
Adrian Trimmings / Michael Burke / Andrew Clark / Lalit Bose
Berenberg (Joint Broker)
+44 (0)20 3207 7800
Toby Flaux / Ben Wright / Ciaran Walsh / Milo Bonser
Camarco (Financial PR)
Geoffrey Pelham-Lane +44 (0)7733 124 226
Ginny Pulbrook +44 (0)7961 315 138
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 Details of the person discharging managerial responsibilities / person closely associated a) Name Ben Jacklin ------------------------------- ---------------------------------- 2 Reason for the notification ------------------------------------------------------------------- a) Position/status Chief Operating Officer ------------------------------- ---------------------------------- b) Initial notification Initial Notification /Amendment ------------------------------- ---------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ------------------------------------------------------------------- a) Name CVS Group plc ------------------------------- ---------------------------------- b) LEI 213800J41XDQ2NX48O05 ------------------------------- ---------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------- a) Description of the financial Ordinary shares of 0.2 pence each instrument, type of instrument GB00B2863827 Identification code b) Nature of the transaction Exercise of options under the 2019 SAYE Plan (1 January 2023 maturity) ----------------------------- ------------------------------------ c) Price(s) and volume(s) Price(s) Volume GBP8.63 709 ----------------------------- ------------------------------------ d) Aggregated information * Aggregated volume N/A - single transaction * Price ----------------------------- ------------------------------------ e) Date of the transaction 10 March 2023 ----------------------------- ------------------------------------ f) Place of the transaction Outside a trading venue ----------------------------- ------------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHJMMMTMTJBBAJ
(END) Dow Jones Newswires
March 10, 2023 05:37 ET (10:37 GMT)
1 Year CVS Chart |
1 Month CVS Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions